Takeda sues Watson and Teva over Rozerem ANDAs
This article was originally published in Scrip
Executive Summary
Takeda Pharmaceutical has filed a patent infringement suit in the US District Court for the District of Delaware against Watson Pharmaceuticals, alleging infringement related to its proposed generic version of the insomnia treatment Rozerem (ramelteon), thus triggering a 30-month stay of approval while the legal battle is fought. The move on December 2nd followed a similar suit filed by Takeda against Teva Pharmaceutical Industries in early November.